Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder

Urology

Volumn 61, Issue 6, 2003, Pages 1140-1145

  Shariat, Shahrokh F ^a   Kim, Jahong ^a   Raptidis, Grigorios ^a   Ayala, Gustavo E ^a   Lerner, Seth P ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR BIOPSY;

EID: 0037602186     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00236-X     Document Type: Article

References (23)

1. Hollstein M., Sidransky D., Vogelstein B., et al. p53 mutations in human cancers. Science. 253:1991;49-53.
2. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
3. Cordon-Cardo C., Dalbagni G., Saez G.T., et al. p53 mutations in human bladder cancer genotypic versus phenotypic patterns. Int J Cancer. 56:1994;347-353.
4. Waga S., Hannon G.J., Beach D., et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
5. Michieli P., Chedid M., Lin D., et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:1994;3391-3395.
6. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 152:1994;388-392.
7. Esrig D., Spruck C.H.D., Nichols P.W., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 143:1993;1389-1397.
8. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma a marker for disease progression . J Natl Cancer Inst. 85:1993;53-59.
9. Spruck C.H. III, Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54:1994;784-788.
10. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 90:1998;1072-1079.
11. Shariat S.F., Weizer A.Z., Green A., et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 56:2000;735-740.
12. Shariat SF, Matsumoto K, Kim J, et al: Association of p53, pRb, p21, and p16 Expression with Pathologic Parameters and Clinical Outcome of Patients with Transitional Cell Carcinoma of the Urinary Bladder. Presented at the 81st Annual Meeting of the South Central Section of the American Urological Association, Colorado Springs, Colorado, October 5-9, 2002.
13. Korkolopoulou P., Konstantinidou A.E., Thomas-Tsagli E., et al. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunohistochem Mol Morphol. 8:2000;285-292.
14. Zlotta A.R., Noel J.C., Fayt I., et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy. J Urol. 161:1999;792-798.
15. Clasen S., Schulz W.A., Gerharz C.D., et al. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer. 77:1998;515-521.
16. Aaltomaa S., Lipponen P., Eskelinen M., et al. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate. 39:1999;8-15.
17. Ferrandina G., Stoler A., Fagotti A., et al. p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol. 17:2000;1231-1235.
18. Cheung T.H., Lo K.W., Yu M.M., et al. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett. 172:2001;93-98.
19. Ceccarelli C., Santini D., Chieco P., et al. Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer. 95:2001;128-134.
20. Malkowicz S.B., Tomaszewski J.E., Linnenbach A.J., et al. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene. 13:1996;1831-1837.
21. Lacombe L., Dalbagni G., Zhang Z.F., et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy correlation to clinical outcome . J Clin Oncol. 14:1996;2646-2652.
22. Ick K., Schultz M., Stout P., et al. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. Urology. 49:1997;541-547.
23. Ovesen H., Horn T., Steven K. Long-term efficacy of intravesical bacillus Calmette-Guérin for carcinoma in situ relationship of progression to histological response and p53 nuclear accumulation . J Urol. 157:1997;1655-1659.